As filed with the Securities and Exchange Commission on November 2, 2016

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

MACROGENICS, INC.

(Exact name of registrant as specified in its charter)

 

     
Delaware   06-1591613

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

     
9704 Medical Center Drive, Rockville, MD   20850
(Address of Principal Executive Offices)   (Zip Code)

 

2016 Employee Stock Purchase Plan
(Full title of the plan)

 

Scott Koenig, M.D., Ph.D.

President and Chief Executive Officer

9704 Medical Center Drive

Rockville, MD 20850

(Name and address of agent for service)

(301) 251-5172

(Telephone number, including area code, of agent for service)

 

Copies to:

Atul Saran

Senior Vice President and General Counsel

9704 Medical Center Drive

Rockville, MD 20850

(301) 251-5172

Keir D. Gumbs

Eric W. Blanchard

Covington & Burling LLP

850 Tenth Street, NW

Washington, DC 20001-4956

(202) 662-6000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller Reporting Company ☐

 

 

CALCULATION OF REGISTRATION FEE

 

Title of securities

to be registered

 

Amount

to be

registered(1)

 

Proposed

maximum

offering price

per share

 

Proposed

maximum

aggregate

offering price

  Amount of
registration fee
Common Stock, $0.01 par value per share  800,000 shares  $23.74(2)  $18,992,000(2)  $2,201.17 

 

(1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

 

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $23.74, the average of the high and low price of the registrant’s Common Stock as reported on the NASDAQ Global Select Market on October 31, 2016.

 

 

 

 

 

PART I

INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

 

Item 1. Plan Information.

 

A prospectus setting forth the information requested by this Item will be sent or given to participants in the plan covered by this registration statement (the “Registration Statement”) pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

 

Item 2. Registration Information and Employee Plan Annual Information.

 

A prospectus setting forth the information requested by this Item is included in documents sent or given to participants in the plan covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act.

 

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Certain Documents by Reference.

 

The Company is subject to the informational and reporting requirements of Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports and other information with the SEC. The following documents, which are on file with the SEC, are incorporated in this Registration Statement by reference:

 

  •  Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including the information specifically incorporated by reference into the Annual Report on Form 10-K from the Company’s definitive proxy statement for the 2016 Annual Meeting of Stockholders;
     
  •  Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2016,  June 30, 2016 and September 30, 2016, respectively;
     
  •  Current Reports on Form 8-K filed on March 1, 2016, March 10, 2016, May 20, 2016, September 12, 2016 and September 20, 2016, respectively; and
     
  •  The description of the Company’s common stock contained in its Registration Statement on Form 8-A filed on October 7, 2013, including any amendments or reports filed for the purpose of updating such description.

 

Any document or any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a subsequently filed document or statement contained therein that is or is also deemed to be incorporated by reference herein modifies or supersedes such document or statement in such document. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Nothing in this Registration Statement shall be deemed to incorporate information furnished but not filed on Form 8-K.

 

 

 

 

 

The Company promptly will provide without charge to each person to whom a prospectus is delivered a copy of any or all information that has been incorporated herein by reference (not including exhibits to the information that is incorporated by reference unless such exhibits are specifically incorporated by reference into such information) upon the written or oral request of such person directed to the General Counsel of the Company at its principal offices, 9704 Medical Center Drive, Rockville, MD 20850, Telephone: (301) 251-5172.

 

Item 8. Exhibits.

 

The exhibits to this Registration Statement are described in the Exhibit Index below.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on November 2, 2016.

 

DATE: November 2, 2016 

 

  By:  /s/ Scott Koenig  
  Name:   Scott Koenig, M.D., Ph.D.  
  Title: President and Chief Executive Officer  

 

 

 

 

 

We, the undersigned directors and officers of MacroGenics, Inc., a Delaware corporation, do hereby constitute and appoint Scott Koenig, M.D., Ph.D., Chief Executive Officer, Atul Saran, General Counsel and James Karrels, Chief Financial Officer, and each and any of them, our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, to do any and all acts and things in our names and on our behalf in our capacities as directors and officers and to execute any and all instruments for us and in our name in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Act and any rules, regulations and requirements of the SEC, in connection with this registration statement, or any registration statement for this offering under the Securities Act, including specifically, but without limitation, any and all amendments (including post-effective amendments) hereto; and we hereby ratify and confirm all that said attorneys and agents, or either of them, shall do or cause to be done by virtue thereof.

 

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons on November 2, 2016.

 

SIGNATURE:   TITLE:
     
/s/ Scott Koenig   President and CEO and Director
Scott Koenig, M.D., Ph.D.   (Principal Executive Officer)
     
/s/ James Karrels   Senior Vice President, Chief Financial Officer and Secretary (Principal Financial Officer)
James Karrels  
     
/s/ Atul Saran   Senior Vice President and General Counsel
Atul Saran  
     
/s/ Lynn Cilinski   Vice President, Controller and Treasurer
(Principal Accounting Officer)
Lynn Cilinski
     
/s/ Paulo Costa   Director
Paulo Costa    
     
/s/ Matthew Fust   Director
Matthew Fust    
     
/s/ Kenneth Galbraith   Director
Kenneth Galbraith    
     
/s/ Edward Hurwitz   Director
Edward Hurwitz    
     
/s/ David Stump   Director
David Stump, M.D.    

 

 

 

 

 

INDEX TO EXHIBITS

 

4.1 Company 2016 Employee Stock Purchase Plan
5.1  Opinion of Covington & Burling LLP
23.1 Consent of Covington & Burling LLP (included in Exhibit 5.1)
23.2    Consent of Ernst & Young LLP
24.1  Power of Attorney (included on signature page)